bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Dec. 23, 2023
ABSTRACT
Cannabidiol
(CBD)
has
gained
a
lot
of
interest
in
recent
years
for
its
purported
medicinal
properties.
CBD
been
investigated
the
treatment
anxiety,
depression,
epilepsy,
neuroinflammation,
and
pain.
Recently
there
an
as
possible
age-related
disorders
such
Alzheimer’s
disease
related
(ADRD).
Here
we
tested
hypothesis
that
chronic
administration
would
improve
learning
memory
SAMP8
mouse
model
disease.
mice
aged
11
months
(at
start
study)
were
administered
vehicle
or
(3
30
mg/Kg)
daily
via
oral
gavage
2
months.
Vehicle-treated
young
(age
3
at
served
unimpaired
controls.
After
days
(4
12
age),
memory,
activity,
strength
dexterity
assessed.
High
dose
significantly
improved
12-month-old
T
maze.
Novel
object
recognition
was
also
by
treated
mice.
Aged
displayed
less
anxiety
elevated
plus
maze
test
compared
to
However,
activity
levels
similar
between
groups.
Biochemical
analysis
revealed
decreased
markers
oxidative
stress,
providing
mechanism
which
impacts
learning,
anxiety.
These
results
highlight
potential
use
therapeutic
age
cognitive
impairment
dementia.
Foods,
Journal Year:
2024,
Volume and Issue:
13(15), P. 2464 - 2464
Published: Aug. 4, 2024
The
purpose
of
this
work
was
to
construct
liver-targeted
nanoparticles
based
on
the
redox
response
effectively
deliver
cannabidiol
(CBD)
for
prevention
acute
liver
injury
(ALI).
CBD-loaded
(CBD
NPs)
with
a
particle
size
126.5
±
1.56
nm
were
prepared
using
polymer
DA-PP-LA
obtained
by
grafting
pullulan
polysaccharide
deoxycholic
acid
(DA)
and
α-lipoic
(α-LA).
CBD
NPs
showed
typical
redox-response
release
behavior.
Interestingly,
exhibited
admirable
targeting
ability,
significantly
accumulated
in
liver,
promoted
internalization
cells,
thus
reducing
H
The
dynamic
interaction
between
carbon
nanodots
(CNDs)
and
cannabidiol
(CBD)
has
captured
significant
attention
as
an
innovative
avenue
for
redefining
drug
delivery
amplifying
therapeutic
effectiveness.
This
in-depth
review
delves
into
the
intricate
synergy
these
two
elements,
unveiling
their
profound
potential
in
medicine.
Commencing
with
examination
of
unique
characteristics
CNDs
techniques
governing
synthesis,
we
discuss
versatility
carriers,
highlighting
invaluable
role
advancing
CBD
delivery.
Cannabidiol,
a
non-psychoactive
compound
sourced
from
cannabis,
emerged
focal
point
its
diverse
attributes.
Nevertheless,
limitations
posed
by
restricted
bioavailability
susceptibility
to
degradation
pose
substantial
hindrances
realizing
full
potential.
Here,
elucidate
how
amalgamation
transcends
challenges.
We
delve
mechanisms
that
underlie
this
synergy,
such
augmentation
solubility
safeguarding
against
premature
breakdown,
providing
analysis.
will
also
journey
you
through
comprehensive
exploration
loading
onto
CNDs,
dissecting
realms
physical
encapsulation,
covalent
bonding,
adsorption
processes.
In
summation,
combination
presents
extraordinary
opportunity
elevate
outcomes.
synergetic
paradigm
masterfully
tackles
pivotal
challenges
delivery,
thereby
paving
path
pioneering
medical
solutions.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 19, 2024
Abstract
Background:
Fundamental
gaps
in
knowledge
exist
understanding
the
tissue
distribution
of
cannabinoids,
cannabidiol
(CBD)
and
tetrahydrocannabinol
(THC),
following
oral
ingestion.
CBD
THC
are
lipid-soluble
bioavailability
is
increased
when
combined
with
long-chain
fatty
acid
carrier
oils
prior
to
Oils
eicosapentaenoic
(EPA)
docosahexaenoic
(DHA)
confer
positive
health
benefits
have
yet
be
examined
as
a
oil
for
cannabinoid
delivery
thus,
examination
warranted.
Methods:
This
study
investigated
acute
cannabinoids
serum,
adipose,
brain,
liver,
heart,
muscle
male
C57BL/6
mice
at
1,
2,
3
hours
(H)
post
Mice
were
gavaged
(5
mg/kg)
(1
either
sesame
(SES),
mixed
EPA/DHA
(EPA/DHA),
or
DHA
enriched
carrier.
With
assistance
Analytical
Facility
Bioactive
Molecules
(Toronto,
Canada),
concentration
was
quantified
using
liquid
chromatography
tandem
mass
spectrometry.
Results:
SES
resulted
significantly
greater
(p<0.05)
across
all
tissues
times
compared
n-3
PUFA
oils.
The
ratio
EPA:DHA
modestly
affected
tissues,
notably,
brain.
Heart
had
highest
1
2H
post-oral
gavage,
adipose
3H
which
consistent
three
Conclusions:
profiled
greatest
number
to-date
consumption
lipid
demonstrated
non-uniform
over
time.
proved
far
more
effective
delivering
orally
consumed
two
different
containing
Further
developing
our
fundamental
their
from
foods
pharmaceuticals
necessary
establish
specific
pharmacokinetic
profiles
aid
dosing
strategies
maximize
bioactive
potential
cannabinoids.
Behavioral and Brain Functions,
Journal Year:
2024,
Volume and Issue:
20(1)
Published: Nov. 1, 2024
The
cannabigerol
derivative
VCE-003.2,
which
has
activity
at
the
peroxisome
proliferator-activated
receptor-γ
afforded
neuroprotection
in
experimental
models
of
Parkinson's
disease
(PD)
based
on
mitochondrial
dysfunction
(6-hydroxydopamine-lesioned
mice)
and
neuroinflammation
(LPS-lesioned
mice).
Now,
we
aim
to
explore
VCE-003.2
neuroprotective
properties
a
PD
model
that
also
involves
protein
dysregulation,
other
key
event
pathogenesis.
Journal of Alzheimer s Disease Reports,
Journal Year:
2024,
Volume and Issue:
8(1), P. 1339 - 1360
Published: March 1, 2024
Background
Alzheimer's
disease
(AD)
is
a
prevalent,
incurable,
and
chronic
neurodegenerative
condition
characterized
by
the
accumulation
of
amyloid-β
protein
(Aβ),
disrupting
various
bodily
systems.
Despite
lack
cure,
phenolic
compounds
like
cannabidiol
(CBD),
non-psychoactive
component
cannabis,
have
emerged
as
potential
therapeutic
agents
for
AD.
Objective
This
systematic
review
explores
impact
different
types
on
AD,
unveiling
their
neuroprotective
mechanisms.
Methods
The
research
used
PubMed,
Scopus,
Web
Science
databases
with
keywords
“Alzheimer's
disease”
“Cannabidiol.”
Studies
were
evaluated
based
title,
abstract,
relevance
to
treating
AD
CBD.
No
restrictions
type
or
publication
year.
Excluded
hypothesis
papers,
reviews,
books,
unavailable
articles,
etc.
Results
Microsoft
Excel
identified
551
92
included
in
study,
but
only
22
thoroughly
evaluated.
In-vivo
in-silico
studies
indicate
that
CBD
may
disrupt
Aβ
42
,
reduce
pro-inflammatory
molecule
release,
prevent
reactive
oxygen
species
formation,
inhibit
lipid
oxidation,
counteract
Aβ-induced
increases
intracellular
calcium,
thereby
protecting
neurons
from
apoptosis.
Conclusions
In
summary,
study
indicates
its
analogs
production
.
Overall,
these
findings
support
alleviating
underlying
pathology
symptoms
associated
underscoring
crucial
need
further
rigorous
scientific
investigation
elucidate
applications
mechanisms
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2023,
Volume and Issue:
unknown
Published: April 12, 2023
Abstract
Mutations
in
the
KCNT1
potassium
channel
cause
severe
forms
of
epilepsy
which
are
resistant
to
current
treatments.
In
vitro
studies
have
shown
that
KCNT1-
mutations
gain
function,
significantly
increasing
K
+
amplitudes.
To
investigate
if
Drosophila
can
be
used
model
human
epilepsy,
we
generated
melanogaster
lines
carrying
with
patient
mutation
G288S,
R398Q
or
R928C.
Expression
each
mutant
GABAergic
neurons
gave
a
seizure
phenotype
was
sensitive
drugs
currently
treat
patients
-epilepsy.
Cannabidiol
showed
greatest
reduction
while
some
increased
phenotype.
Our
study
shows
-epilepsy
and
potentially
as
tool
assess
new
treatments
for
epilepsy.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Dec. 23, 2023
ABSTRACT
Cannabidiol
(CBD)
has
gained
a
lot
of
interest
in
recent
years
for
its
purported
medicinal
properties.
CBD
been
investigated
the
treatment
anxiety,
depression,
epilepsy,
neuroinflammation,
and
pain.
Recently
there
an
as
possible
age-related
disorders
such
Alzheimer’s
disease
related
(ADRD).
Here
we
tested
hypothesis
that
chronic
administration
would
improve
learning
memory
SAMP8
mouse
model
disease.
mice
aged
11
months
(at
start
study)
were
administered
vehicle
or
(3
30
mg/Kg)
daily
via
oral
gavage
2
months.
Vehicle-treated
young
(age
3
at
served
unimpaired
controls.
After
days
(4
12
age),
memory,
activity,
strength
dexterity
assessed.
High
dose
significantly
improved
12-month-old
T
maze.
Novel
object
recognition
was
also
by
treated
mice.
Aged
displayed
less
anxiety
elevated
plus
maze
test
compared
to
However,
activity
levels
similar
between
groups.
Biochemical
analysis
revealed
decreased
markers
oxidative
stress,
providing
mechanism
which
impacts
learning,
anxiety.
These
results
highlight
potential
use
therapeutic
age
cognitive
impairment
dementia.
